These findings suggest that AXL signaling is likely not the sole driver of ERK reactivation and that adaptive resistance should continue to be investigated to find additional strategies to improve treatment for patients with FLT3/ITD AML. This evidence concerns the gene AXL and acute myeloid leukemia.